Transparency of reporting in molecular diagnostics by Bustin, Stephen A.
Int. J. Mol. Sci. 2013, 14, 15878-15884; doi:10.3390/ijms140815878 
 





Transparency of Reporting in Molecular Diagnostics 
Stephen Bustin 
Postgraduate Medical Institute, Anglia Ruskin University, Chelmsford CM1 1SQ, UK;  
E-Mail: stephen.bustin@anglia.ac.uk; Tel.: +44-0-845-196-4845  
Received: 3 July 2013; in revised form: 23 July 2013 / Accepted: 23 July 2013 /  
Published: 30 July 2013 
 
The major advances made over the past few years in molecular and cell biology are providing a 
progressively more detailed understanding of the molecular pathways that control normal processes 
and become dysregulated in disease [1]. This has resulted in the documentation of numerous genetic, 
epigenetic, transcriptomic, proteomic and metabolomic biomarkers that promise earlier disease 
detection, more accurate patient stratification and better prognosis [2–5]. Furthermore, molecular 
fingerprinting of diseases can be predictive of drug response and so assist with specific targeting of 
drugs against disease-associated molecules and function [6].  
This, together with the continuous appearance of new technologies, is leading to the introduction of 
new tools and emergent applications for molecular diagnostics (MDx), usually defined as the detection 
of changes associated with certain states of health or disease using molecular methods [7]. MDx has 
the potential to transform modern health care by combining speed and accuracy with low cost to 
improve health outcomes for individual patients as well as reducing expenditure by health care 
providers. However, it is also important to consider the implications of the often-unexpected 
complexity and heterogeneity of diseases that have become apparent as a result of their molecular 
dissections [2,8].  
MDx has become more than just analysis of genetic content for disease information, and makes use 
of a range of techniques including isothermal amplification methods [9], nucleic acid sequencing [10], 
high resolution melt analysis [11], DNA microarrays [12], tissue arrays [13], mass spectrometry [14], 
nanoparticles [15] and fluorescence in situ hybridisation [16]. Perhaps the most ubiquitous molecular 
technique is the real-time quantitative polymerase chain reaction (qPCR) [17], which can detect DNA, 
RNA (reverse transcription (RT)-qPCR) and proteins (proximity ligation/extension assay). Together, 
these methods address three distinct categories of clinical questions: 
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x Pathogen detection, for example by screening for pathogen-specific nucleic acids, proteins or 
metabolites. One of the strengths of molecular diagnostic techniques is their capacity to vary 
their specificity from the detection of a single strain (e.g., Escherichia coli O157:H7) to that of 
a species (e.g., Aspergillus). 
x Expression profiling, which aims to detect disease-associated changes to coding and  
non-coding cellular RNA and which is beginning to include the analysis of protein-based 
markers [18].  
x Genetic testing, which generally refers to screening for host-derived, epigenetically or genetically 
altered DNA [19]. 
These questions are addressed in the context of many clinical application areas. Arguably at the 
forefront are infectious diseases, where MDx has become part of the routine workload in most clinical 
laboratories [20] and is having a major impact on clinical decision-making [21]. Sepsis, for example, is 
among the most common causes of death in hospitals and MDx promises to transform sepsis from a 
physiologic syndrome into a group of distinct biochemical disorders, thus helping in the development 
of better diagnostic tools and effective adjunctive sepsis therapies [22]. Several molecular detection 
techniques are in use for the reliable identification of a targeted pathogen, with qPCR today’s “gold” 
standard of diagnosis [23].  
Oncological applications are also on the increase [24], based on the discovery of differential mRNA 
and miRNA expression patterns, cell surface proteins and other molecular attributes associated with 
cancers. They are closely linked to pharmacogenomics uses [25], which aim to correlate the influence 
of genetic variation with drug response and so develop drugs that target molecular pathways 
implicated in diseased cells without affecting normal cells. These novel tests may help realise the most 
anticipated development from MDx: personalised medicine, which optimises patient outcomes and 
healthcare use by utilising an individual’s genetic makeup to tailor an individual treatment plan that is 
administered at the right time and at the right dose. Examples include breast cancers that overexpress 
HER2 [26], colorectal cancers that are mutated in the BRAF gene [27], chronic myeloid leukaemias 
that do not respond to the tyrosine kinase inhibitor imatinib [28] and gastrointestinal stromal tumours 
with selective c-kit oncogene activating mutations [29].  
Third, MDx are becoming of increasing importance for the screening of genetic alterations [30],  
an application whose importance can only increase and is certain to influence the management of 
diseases [31]. 
The IJMS has developed a reputation for the quality of its contributions and proposes to develop an 
enhanced focus on this rapidly expanding area of molecular science. We encourage the submission of 
high quality reviews, research articles and short communications that place special emphasis on the 
translation of research discoveries into practice, describe novel or improved technologies and their 
applications, and are characterised by an emphasis on transparency of reporting. This includes 
manuscripts discussing new bioinformatic concepts and programs that advance our understanding of 
the link between molecular data and physiology or pathophysiology. 
A major problem with many peer-reviewed publications is that they propagate conclusions that 
cannot be reproduced elsewhere, and so contribute to the challenge of distinguishing biologically valid 
conclusions from those that are based on technical errors, analytical inaccuracies or interpretative 
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misinterpretations [32]. An important reason for this is the reluctance of many journals to provide 
sufficient space for the publication of detailed experimental protocols, denying readers an opportunity 
to assess the reliability and validity of the experimental approach and protocol details.  
One area of particular concern has been the quantification of nucleic acids by qPCR, whose 
superficial simplicity, sensitivity and specificity make it the most widely used method for MDx 
applications. Those attributes are gainsaid by their actual complexity and inconsistency, which in 
practice means that the biological relevance of many published qPCR-based results is open to 
question, with reported differences caused by technical, rather than actual, variability [32]. There has 
been an extensive effort over the last twelve years to make researchers aware of the pitfalls of this 
technology [33–43], culminating in the publication of guidelines for the minimum information for the 
publication of qPCR (MIQE) [44] and digital PCR (dPCR, dMIQE) [45] experiments. These 
guidelines aim to enable authors to design and report qPCR experiments that have greater inherent 
value, allow reviewers and editors to measure the technical quality of submitted manuscripts against an 
established yardstick and facilitate easier replication of experiments described in published studies that 
follow these guidelines. They have become widely accepted, with more than 1600 citations in the  
peer-reviewed literature, and have paved the way for the recent editorial announcement in Nature and 
the Nature research journals, which admit their failure to exert sufficient scrutiny over the results that 
they publish and acknowledge that they have not published enough information for other researchers to 
assess results properly [46]. There have been editorials in BioMedCentral (BMC) Molecular  
Biology [47] and the Veterinary Journal [48] promoting the idea of the submission of comprehensive 
experimental protocols, with Nucleic Acids Research, Peer J, Molecular Medicine, European Urology, 
The Journal of Clinical Microbiology, The Journal of Molecular Medicine as well as Reproduction  
and Fertility and Development recommending and Clinical Chemistry requiring adherence to the 
essential MIQE parameters. Other techniques used in MDx, including microarrays [49] and mass 
spectrometry [50], suffer from similar challenges that are quite familiar to experts but less obvious to 
the general reviewer or reader of a publication.  
Consequently, the editorial team reviewing and accepting publications in the IJMS will implement 
measures that safeguard the transparency and quality of any publication appearing in this journal. This 
means that there will be emphasis on the publication of comprehensive technical detail sufficient to 
allow the interested reader to reproduce accurately any experimental protocols. For nucleic acid-based 
techniques, there will be particular emphasis on quality assessment—critical especially for methods 
targeting RNA [51]—assay design and efficiency and normalisation procedures. Ideally, this information 
will be published in the form of a supplementary file that will include the following information:  
x Nucleic acid purity: absence of inhibitors that can interfere with the reverse transcription, PCR 
or hybridisation stages of assays. This is easily established by using a nucleic acid spike, e.g., 
the SPUD assay [52], or a 10-fold dilution test to check for inhibition. 
x RNA integrity: established by means of a microfluidic analysis of the RNA [53] or a 3':5' 
assessment of target or reference RNAs [54]. 
x Assay design/PCR efficiency: primers and probes used for PCR reactions should be published 
with individual papers and not just be referenced, since the referenced publication is frequently 
not on open access, making it more difficult than necessary to identify the details of the assays 
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used. It is also essential to publish information about the efficiency of the PCR assay, as this 
provides useful information about the robustness and sensitivity of the assay in question.  
x Normalisation: this should be against validated reference genes [55] appropriate for the  
fold-differential expression claimed for mRNAs [56] as well as for miRNAs [57,58].  
These criteria are especially aimed at publications utilising RT-qPCR and qPCR-based results, since 
they form the vast majority of all reported MDx data. However, there is an obvious need to provide 
protocols of similar transparency and completeness for other techniques; for example, evidence should 
be provided for absence of amplification bias when pre-amplifying limited sample material, and 
evidence of appropriate verification is required for the new high-throughput RNA Seq or small-RNA 
Seq data. For microarray data there will need to be some indication of the accuracy, precision and 
specificity of the data presented for publication [59], ideally with corroboration by an alternative 
method such as RT-qPCR. For mass spectrometry there will need to be evidence for satisfactory peak 
shape, mass resolution and calibration as well as a noise-free background spectrum.  
All of the information requested will become available during the course of an appropriately 
conducted experiment; hence it does not constitute an additional workload. Sharing those basic data 
will ensure that the journal publishes results and conclusions whose underlying technical fitness is 
beyond doubt, allowing readers to focus on the biological and clinical relevance of the results. 
Ultimately, this approach will enhance the reputation of both journals and publications, which is in all 
our interest. 
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